TCTR20230424002已完成4 期
SARS-CoV-2 antibody response after a booster dose of the mRNA COVID-19 vaccine (BNT162b2) among Thai children and adolescents aged 5-17 years.
Siriraj Grant for Research Development0 个研究点目标入组 150 人开始时间: 2023年4月24日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5 Years 至 17 Years（—）
- 性别
- All
入选标准
- •1. The subject is aged 5 to less than 18 years. 2. Have received two doses of full dose mRNA COVID-19 vaccine 3. Have received 2nd dose of COVID-19 vaccine for at least 3 months at the time of third vaccination 4. Have no history of detecting SARS-CoV-2 infection 5. Can understand Thai language through speaking, reading, and writing 6. Capable of attending all study visits according to the study schedule
排除标准
- •1. Have any history of severe drug or vaccine allergy (anaphylaxis) 2. Have a history of Myocarditis or pericarditis from the mRNA COVID-19 vaccine 3. Have received any other vaccines within 14 days for live vaccines or 28 days for inactivated vaccines (excepted influenza vaccine) 4. Have body temperature more than equal 38 C or 100.4 F within 24 hours prior received study vaccine 5. Subject who are pregnant 6. Have received blood transfusion, plasma, blood product, blood components, immunoglobulins, antiviral, or antibodies within the last 90 days 7. Have any history of immunodeficiency or received immunosuppressants or received steroids drugs 8. Have any conditions that are considered unsuitable for clinical study by the investigator
研究者
相似试验
已完成
不适用
Changes in antibody titer after SARS-CoV-2 vaccination of patients with in-center and home dialysisJPRN-UMIN000046281Reiseikai Medical Corporation Shinagawa Garden Clinic96
尚未招募
不适用
Can vaccination produce protective antibodies in people who fail to develop protective antibodies after recovery from COVID-19 infectioCTRI/2021/04/032572Rajiv Gandhi Cancer Institute and Research Centre
尚未招募
不适用
A study on post- vaccination IgG antibody status among the healthcare workersCTRI/2021/03/031986Rajarajeswari medical college and hoapital
已完成
4 期
Intradermal second booster COVID-19 vaccinatioThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2.booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, ThailandTCTR20230411008Faculty of Medicine Siriraj hospital, Mahidol University107
进行中（未招募）
1 期
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570